Skip to main content
SpringerLink
Log in

Injectables: Aesthetics and Cosmetics

  • Chapter
  • First Online:
Current Advances in Ocular Surgery

Part of the book series: Current Practices in Ophthalmology ((CUPROP))

  • 260 Accesses

Abstract

Soft tissue fillers have gained tremendous popularity as a minimally invasive intervention for restoring volume loss and facial symmetry due to chronological aging, disease, and trauma [1]. The use of filler for facial reconstruction dates back the 1830s when the first injectable agent, paraffin was introduced followed by autologous fat in the 1890s. It was not until 1981, when Zyderm®, a bovine collagen filler, became the first Food and Drug Administration (FDA) approved agent for soft tissue reconstruction [2, 3]. Since then, various agents have been developed. In 2003, the FDA approved Restylane®, a product made from hyaluronic acid (HA). Shortly after, the market for dermal fillers experienced rapid growth with over 2.5 million injectable procedures performed in the United States in 2019 alone [4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jones DH, Bacigalupi R, Beleznay K. Injectable soft tissue augmentation. Bolognia Dermatol. 2018:2649–59.

    Google Scholar 

  2. Eppley BL, Dadvand B. Injectable soft-tissue fillers: clinical overview. Plast Reconstr Surg. 2006;118(4):98–106. https://doi.org/10.1097/01.prs.0000232436.91409.30.

    Article  CAS  Google Scholar 

  3. Kontis TC, Rivkin A. The history of injectable facial fillers. Facial Plast Surg. 2009;25(2):67–72. https://doi.org/10.1055/s-0029-1220645.

    Article  CAS  PubMed  Google Scholar 

  4. Aesthetic Plastic Surgery National Databank Statistics.; 2019. Accessed August 1, 2021. https://www.surgery.org/sites/default/files/Aesthetic-Society_Stats2019Book_FINAL.pdf

  5. Kotlus BS, Dryden RM. Correction of Anophthalmic Enophthalmos with injectable calcium hydroxyapatite (Radiesse). Ophthal Plast Reconstr Surg. 2007;23(4):313–4. https://doi.org/10.1097/IOP.0b013e31806ada5c.

    Article  PubMed  Google Scholar 

  6. Tan P, Kwong TQ, Malhotra R. Non-aesthetic indications for periocular hyaluronic acid filler treatment: a review. Br J Ophthalmol. 2018;102(6):725–35. https://doi.org/10.1136/bjophthalmol-2017-310525.

    Article  PubMed  Google Scholar 

  7. Hassan Hussien M, Abd El-Wahed Hassan E, El-Haddad NSE-DM. Comparison between hyaluronic acid filler and botulinum toxin type A in the treatment of thyroid upper eyelid retraction. Ther Adv Ophthalmol. 2020;12:251584142097911. https://doi.org/10.1177/2515841420979113.

    Article  Google Scholar 

  8. Carruthers J, Humphrey S. Injectable soft tissue fillers: Overview of clinical use.; 2021. https://www.uptodate.com/contents/injectable-soft-tissue-fillers-overview-of-clinical-use/print?source=history_widgetwww.uptodate.com

  9. Jones DH. Semipermanent and permanent injectable fillers. Dermatol Clin. 2009;27(4):433–44. https://doi.org/10.1016/j.det.2009.08.003.

    Article  CAS  PubMed  Google Scholar 

  10. Funt D, Pavicic T. Dermal fillers in aesthetics: an overview of adverse events and treatment approaches. Clin Cosmet Investig Dermatol. 2013;6:295–316. https://doi.org/10.2147/CCID.S50546.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Bellafill-Instructions for Use. Accessed 1 Aug 2021. https://www.accessdata.fda.gov/cdrh_docs/pdf2/P020012S009c.pdf

  12. Liberati A, Altman D, Tetzlaff J, et al. Malar augmentation with polymethylmethacrylate-enhanced filler: assessment of a 12-month open-label pilot study. Aesthetic Surg J. 2013;33(3):539–47.

    Google Scholar 

  13. Aquamid. Published 2019. https://www.aquamid.com/wp-content/uploads/2019/11/Aquamid-Brochure_Physician.pdf

  14. Fallacara A, Manfredini S, Durini E, Vertuani S. Hyaluronic acid fillers in soft tissue regeneration. Facial Plast Surg. 2017;33(1):87–96. https://doi.org/10.1055/s-0036-1597685.

    Article  CAS  PubMed  Google Scholar 

  15. Sapijaszko MJ. Dermal fillers: ever-expanding options for esthetic use. Skin Therapy Lett. 2007;12(8):4–7.

    CAS  PubMed  Google Scholar 

  16. Kontis TC. Contemporary review of injectable facial fillers. JAMA Facial Plast Surg. 2013;15(1):58–64. https://doi.org/10.1001/jamafacial.2013.337.

    Article  PubMed  Google Scholar 

  17. Heitmiller K, Ring C, Saedi N. Rheologic properties of soft tissue fillers and implications for clinical use. J Cosmet Dermatol.

    Google Scholar 

  18. Gupta N, Spiegel OL, Spiegel JH. Radiesse™ calcium hydroxyapatite injectable filler. Neurotoxins Fill Facial Esthet Surg. 2019:71–4. https://doi.org/10.1002/9781119294306.ch5.

  19. Montes JR, Santos E, Amaral C. Eyelid and periorbital dermal fillers: products, techniques, and outcomes. Facial Plast Surg Clin North Am. 2021;29(2):335–48. https://doi.org/10.1016/j.fsc.2021.01.003.

    Article  PubMed  Google Scholar 

  20. Lee JC, Lorenc ZP. Synthetic fillers for facial rejuvenation. Clin Plast Surg. 2016;43(3):497–503. https://doi.org/10.1016/j.cps.2016.03.002.

    Article  PubMed  Google Scholar 

  21. Herrmann JL, Hoffmann RK, Ward CE, Schulman JM, Grekin RC. Biochemistry, physiology, and tissue interactions of contemporary biodegradable injectable dermal fillers. Dermatol Surg. 2018;44:S19–31. https://doi.org/10.1097/DSS.0000000000001582.

    Article  CAS  PubMed  Google Scholar 

  22. Lighthall JG. Rejuvenation of the upper face and brow: neuromodulators and fillers. Facial Plast Surg. 2018;34(2):119–27. https://doi.org/10.1055/s-0038-1637004.

    Article  CAS  PubMed  Google Scholar 

  23. Lee W, Hwang SG, Oh W, Kim CY, Lee JL, Yang EJ. Practical guidelines for hyaluronic acid soft-tissue filler use in facial rejuvenation. Dermatol Surg. 2020;46(1):41–9. https://doi.org/10.1097/DSS.0000000000001858.

    Article  CAS  PubMed  Google Scholar 

  24. Rohrich RJ, Bartlett EL, Dayan E. Practical approach and safety of hyaluronic acid fillers. Plast Reconstr Surg Glob Open. 2019;7(6):e2172. https://doi.org/10.1097/gox.0000000000002172.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Lemperle G, Rullan PP, Gauthier-Hazan N. Avoiding and treating dermal filler complications. Plast Reconstr Surg. 2006;118(3 suppl):92S. https://doi.org/10.1097/01.prs.0000234672.69287.77.

    Article  CAS  PubMed  Google Scholar 

  26. Tran AQ, Topilow N, Rong A, et al. Comparison of skin antiseptic agents and the role of 0.01% hypochlorous acid. Aesthetic Surg J. 2021;41(10):1170–5. https://doi.org/10.1093/asj/sjaa322.

    Article  Google Scholar 

  27. Lee WW, Watson C, Topilow NJ, Pirakitikulr N, Tran AQ. Botulinum toxins and soft tissue fillers. Albert Jakobiec’s Princ Pract Ophthalmol. 2020:1–23. https://doi.org/10.1007/978-3-319-90495-5_92-1.

  28. Tran AQ, Staropoli P, Rong AJ, Lee WW. Filler-associated vision loss. Facial Plast Surg Clin North Am. 2019;27(4):557–64. https://doi.org/10.1016/j.fsc.2019.07.010.

    Article  PubMed  Google Scholar 

  29. Wollina U, Goldman A. Facial vascular danger zones for filler injections. Dermatol Ther. 2020;33(6) https://doi.org/10.1111/dth.14285.

  30. Kapoor KM, Bertossi D, Li CQ, Saputra DI, Heydenrych I, Yavuzer R. A systematic literature review of the middle temporal vein anatomy: ‘venous danger zone’ in temporal fossa for filler injections. Aesthet Plast Surg. 2020;44(5):1803–10. https://doi.org/10.1007/s00266-020-01791-2.

    Article  Google Scholar 

  31. De Maio M, DeBoulle K, Braz A, Rohrich RJ. Facial assessment and injection guide for botulinum toxin and injectable hyaluronic acid fillers: focus on the midface. Plast Reconstr Surg. 2017;140(4):540E–50E. https://doi.org/10.1097/PRS.0000000000003716.

    Article  CAS  PubMed  Google Scholar 

  32. Hufschmidt K, Bronsard N, Foissac R, et al. The infraorbital artery: clinical relevance in esthetic medicine and identification of danger zones of the midface. J Plast Reconstr Aesthetic Surg. 2019;72(1):131–6. https://doi.org/10.1016/j.bjps.2018.09.010.

    Article  CAS  Google Scholar 

  33. Sharad J. Treatment of the tear trough and infraorbital hollow with hyaluronic acid fillers using both needle and cannula. Dermatol Ther. 2020;33(3):e13353. https://doi.org/10.1111/dth.13353.

    Article  PubMed  Google Scholar 

  34. Restylane Contour. Published 2021. Accessed 9 Nov 2021. www.fda.gov/medical-devices/recently-approved/restylaner-contour-p140029s032

  35. Trinh LN, Grond SE, Gupta A. Dermal fillers for tear trough rejuvenation: a systematic review. Facial Plast Surg. 2021;38:228. https://doi.org/10.1055/s-0041-1731348.

    Article  CAS  PubMed  Google Scholar 

  36. Ogilvie P, Thulesen J, Leys C, et al. Expert consensus on injection technique and area-specific recommendations for the hyaluronic acid dermal filler VYC-12L to treat fine cutaneous lines. Clin Cosmet Investig Dermatol. 2020;13:267–74. https://doi.org/10.2147/CCID.S239667.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. FDA executive summary general issues panel meeting on dermal fillers. Published online 2021:1–38. https://www.fda.gov/media/146870/download

  38. Monheit G, Kaufman-Janette J, Joseph JH, Shamban A, Dover JS, Smith S. Efficacy and safety of two resilient hyaluronic acid fillers in the treatment of moderate-to-severe nasolabial folds: a 64-week, prospective, multicenter, controlled, randomized, double-blinded, and within-subject study. Dermatol Surg. 2020;46(12):1521–9. https://doi.org/10.1097/DSS.0000000000002391.

    Article  CAS  PubMed  Google Scholar 

  39. De Maio M, Wu WTL, Goodman GJ, Monheit G. Facial assessment and injection guide for botulinum toxin and injectable hyaluronic acid fillers: focus on the lower face. Plast Reconstr Surg. 2017;140(3):393E–404E. https://doi.org/10.1097/PRS.0000000000003646.

    Article  CAS  PubMed  Google Scholar 

  40. Allemann IB, Baumann L. Hyaluronic acid gel (Juvéderm™) preparations in the treatment of facial wrinkles and folds. Clin Interv Aging. 2008;3(4):629–34. https://doi.org/10.2147/CIA.S3118.

    Article  CAS  PubMed Central  Google Scholar 

  41. Ogilvie P, Benouaiche L, Philipp-Dormston WG, et al. VYC-25L hyaluronic acid injectable gel is safe and effective for long-term restoration and creation of volume of the lower face. Aesthetic Surg J. 2020;40(9):NP499–510. https://doi.org/10.1093/asj/sjaa013.

    Article  Google Scholar 

  42. King M, Convery C, Davies E. The use of hyaluronidase in aesthetic practice (v2.4). J Clin Aesthet Dermatol. 2018;11(6):E61–8.

    PubMed  PubMed Central  Google Scholar 

  43. Alijotas-Reig J, Fernández-Figueras MT, Puig L. Inflammatory, immune-mediated adverse reactions related to soft tissue dermal fillers. Semin Arthritis Rheum. 2013;43(2):241–58. https://doi.org/10.1016/j.semarthrit.2013.02.001.

    Article  CAS  PubMed  Google Scholar 

  44. Christensen L. Normal and pathologic tissue reactions to soft tissue gel fillers. Dermatologic Surg. 2007;33(suppl. 2) https://doi.org/10.1111/j.1524-4725.2007.33357.x.

  45. Lafaille P, Benedetto A. Fillers: contraindications, side effects and precautions. J Cutan Aesthet Surg. 2010;3(1):16. https://doi.org/10.4103/0974-2077.63222.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Witmanowski H, Błochowiak K. Another face of dermal fillers. Postep Dermatologii i Alergol. 2020;37(5):651–9. https://doi.org/10.5114/ada.2019.82859.

    Article  Google Scholar 

  47. Robati RM, Moeineddin F, Almasi-Nasrabadi M. The risk of skin necrosis following hyaluronic acid filler injection in patients with a history of cosmetic rhinoplasty. Aesthetic Surg J. 2018;38(8):883–8. https://doi.org/10.1093/asj/sjy005.

    Article  Google Scholar 

  48. Zein M, Tie-Shue R, Pirakitikulr N, Lee WW. Complications after cosmetic periocular filler: prevention and management. Plast Aesthetic Res. 2020;7:44. https://doi.org/10.20517/2347-9264.2020.133.

    Article  Google Scholar 

  49. Rayess HM, Svider PF, Hanba C, et al. A cross-sectional analysis of adverse events and litigation for injectable fillers. In: JAMA facial plastic surgery, vol. 20. American Medical Association; 2018. p. 207–14. https://doi.org/10.1001/jamafacial.2017.1888.

    Chapter  Google Scholar 

  50. Lee W, Koh IS, Oh W, Yang EJ. Ocular complications of soft tissue filler injections: a review of literature. J Cosmet Dermatol. 2020;19(4):772–81. https://doi.org/10.1111/jocd.13213.

    Article  PubMed  Google Scholar 

  51. Sito G, Manzoni V, Sommariva R. Vascular complications after facial filler injection: a literature review and meta-analysis. J Clin. 2019;12(6):e65–72.

    Google Scholar 

  52. Ansari ZA, Choi CJ, Rong AJ, Erickson BP, Tse DT. Ocular and cerebral infarction from periocular filler injection. Orbit (London). 2019;38(4):322–4. https://doi.org/10.1080/01676830.2018.1537287.

    Article  Google Scholar 

  53. Kim YJ, Kim SS, Song WK, Lee SL, Yoon JS. Ocular ischemia with hypotony after injection of hyaluronic acid gel. Ophthal Plast Reconstr Surg. 2011;27(6):e152–5. https://doi.org/10.1097/IOP.0b013e3182078dff.

    Article  PubMed  Google Scholar 

  54. Shone C, Appleton N, Wilton-Smith P, et al. In vitro assays for botulinum toxin and antitoxins. Dev Biol Stand. 1986;64:141–5.

    CAS  PubMed  Google Scholar 

  55. Peck MW, Smith TJ, Anniballi F, et al. Historical perspectives and guidelines for botulinum neurotoxin subtype nomenclature. Toxins. 2017;9(1):38. https://doi.org/10.3390/toxins9010038.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Scott AB. Development of botulinum toxin therapy. Dermatol Clin. 2004;22(2):131–3. https://doi.org/10.1016/S0733-8635(03)00019-6.

    Article  PubMed  Google Scholar 

  57. Botulinum toxin type A—product approval information—licensing action. Accessed 6 Sep 2021. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/botuall041202L.htm

  58. 2020 Plastic surgery statistics report. Plast Surg. Published online 2020:26.

    Google Scholar 

  59. Persaud R, Garas G, Silva S, Stamatoglou C, Chatrath P, Patel K. An evidence-based review of botulinum toxin (Botox) applications in non-cosmetic head and neck conditions. JRSM Short Rep. 2013;4(2):1–9. https://doi.org/10.1177/2042533312472115.

    Article  Google Scholar 

  60. Vanuytsel T, Bisschops R, Farré R, et al. Botulinum toxin reduces dysphagia in patients with nonachalasia primary esophageal motility disorders. Clin Gastroenterol Hepatol. 2013;11(9):1115–1121.e2. https://doi.org/10.1016/j.cgh.2013.03.021.

    Article  CAS  PubMed  Google Scholar 

  61. Marsili L, Bologna M, Jankovic J, Colosimo C. Long-term efficacy and safety of botulinum toxin treatment for cervical dystonia: a critical reappraisal. Expert Opin Drug Saf. 2021;20(6):695–705. https://doi.org/10.1080/14740338.2021.1915282.

    Article  PubMed  Google Scholar 

  62. Coffield JA, Bakry N, Zhang RD, Carlson J, Gomella LG, Simpson LL. In vitro characterization of botulinum toxin types A, C and D action on human tissues: combined electrophysiologic, pharmacologic and molecular biologic approaches. J Pharmacol Exp Ther. 1997;280(3):1489–98.

    CAS  PubMed  Google Scholar 

  63. Niemann H, Binz T, Grebenstein O, et al. Clostridial neurotoxins: from toxins to therapeutic tools? Behring Inst Mitt. 1991;89:153–62.

    CAS  Google Scholar 

  64. Schiavo G, Benfenati F, Poulain B, et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature. 1992;359(6398):832–5. https://doi.org/10.1038/359832a0.

    Article  CAS  PubMed  Google Scholar 

  65. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl. 1997;6:S146–68.

    Article  CAS  PubMed  Google Scholar 

  66. Walker TJ, Dayan SH. Comparison and overview of currently available neurotoxins. J Clin Aesthetic Dermatol. 2014;7(2):31–9.

    Google Scholar 

  67. Klein AW, Carruthers A, Fagien S, Lowe NJ. Comparisons among botulinum toxins: an evidence-based review. Plast Reconstr Surg. 2008;121(6):413e. https://doi.org/10.1097/PRS.0b013e318170813c.

    Article  CAS  PubMed  Google Scholar 

  68. Won CH, Kim HK, Kim BJ, et al. Comparative trial of a novel botulinum neurotoxin type a versus onabotulinumtoxinA in the treatment of glabellar lines: a multicenter, randomized, double-blind, active-controlled study. Int J Dermatol. 2015;54(2):227–34. https://doi.org/10.1111/ijd.12627.

    Article  CAS  PubMed  Google Scholar 

  69. Ravenni R, De Grandis D, Mazza A. Conversion ratio between Dysport and Botox in clinical practice: an overview of available evidence. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2013;34(7):1043–8. https://doi.org/10.1007/s10072-013-1357-1.

    Article  Google Scholar 

  70. Scaglione F. Conversion ratio between Botox®, Dysport®, and Xeomin® in clinical practice. Toxins. 2016;8(3):65. https://doi.org/10.3390/toxins8030065.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Gadarowski MB, Ghamrawi RI, Taylor SL, Feldman SR. PrabotulinumtoxinA-xvfs for the treatment of moderate-to-severe glabellar lines. Ann Pharmacother. 2021;55(3):354–61. https://doi.org/10.1177/1060028020943527.

    Article  CAS  PubMed  Google Scholar 

  72. What is Jeuveau and Can It Beat Botox? | Faces PLLC. Faces, PLLC in Ridgeland, MS. Published July 30, 2019. Accessed September 6, 2021. https://www.facesdr.com/what-is-jeuveau-and-can-it-beat-botox/

  73. Klein AW. Complications, adverse reactions, and insights with the use of botulinum toxin. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2003;29(5):549–56; discussion 556. https://doi.org/10.1046/j.1524-4725.2003.29129.x.

    Article  Google Scholar 

  74. Cheng CM. Cosmetic use of botulinum toxin type a in the elderly. Clin Interv Aging. 2007;2(1):81–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Hexsel DM, De Almeida AT, Rutowitsch M, et al. Multicenter, double-blind study of the efficacy of injections with botulinum toxin type a reconstituted up to six consecutive weeks before application. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2003;29(5):523–9; discussion 529. https://doi.org/10.1046/j.1524-4725.2003.29121.x.

    Article  Google Scholar 

  76. Hui JI, Lee WW. Efficacy of fresh versus refrigerated botulinum toxin in the treatment of lateral periorbital rhytids. Ophthal Plast Reconstr Surg. 2007;23(6):433–8. https://doi.org/10.1097/IOP.0b013e31815793b7.

    Article  PubMed  Google Scholar 

  77. Sami MS, Soparkar CNS, Patrinely JR, Hollier LM, Hollier LH. Efficacy of botulinum toxin type a after topical anesthesia. Ophthal Plast Reconstr Surg. 2006;22(6):448–52. https://doi.org/10.1097/01.iop.0000248989.33572.3c.

    Article  PubMed  Google Scholar 

  78. Kuwahara H, Ogawa R. Using a vibration device to ease pain during facial needling and injection. Eplasty. 2016;16:e9.

    PubMed  PubMed Central  Google Scholar 

  79. Sharma P, Czyz CN, Wulc AE. Investigating the efficacy of vibration anesthesia to reduce pain from cosmetic botulinum toxin injections. Aesthet Surg J. 2011;31(8):966–71. https://doi.org/10.1177/1090820X11422809.

    Article  PubMed  Google Scholar 

  80. Ahn BK, Kim YS, Kim HJ, Rho NK, Kim HS. Consensus recommendations on the aesthetic usage of botulinum toxin type a in Asians. Dermatol Surg. 2013;39(12):1843–60. https://doi.org/10.1111/dsu.12317.

    Article  CAS  PubMed  Google Scholar 

  81. Zhang X, Cai L, Yang M, Li F, Han X. Botulinum toxin to treat horizontal forehead lines: a refined injection pattern accommodating the lower frontalis. Aesthet Surg J. 2020;40(6):668–78. https://doi.org/10.1093/asj/sjz174.

    Article  CAS  PubMed  Google Scholar 

  82. Rzany B, Ascher B, Fratila A, Monheit GD, Talarico S, Sterry W. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol. 2006;142(3):320–6. https://doi.org/10.1001/archderm.142.3.320.

    Article  CAS  PubMed  Google Scholar 

  83. Lowe PL, Patnaik R, Lowe NJ. A comparison of two botulinum type a toxin preparations for the treatment of glabellar lines: double-blind, randomized, pilot study. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2005;31(12):1651–4. https://doi.org/10.2310/6350.2005.31303.

    Article  CAS  Google Scholar 

  84. Frankel AS, Kamer FM. Chemical browlift. Arch Otolaryngol Head Neck Surg. 1998;124(3):321–3. https://doi.org/10.1001/archotol.124.3.321.

    Article  CAS  PubMed  Google Scholar 

  85. Huang W, Rogachefsky AS, Foster JA. Browlift with botulinum toxin. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2000;26(1):55–60. https://doi.org/10.1046/j.1524-4725.2000.99147.x.

    Article  CAS  Google Scholar 

  86. Ahn MS, Catten M, Maas CS. Temporal brow lift using botulinum toxin A. Plast Reconstr Surg. 2000;105(3):1129–35; discussion 1136–1139. https://doi.org/10.1097/00006534-200003000-00046.

    Article  CAS  PubMed  Google Scholar 

  87. Hwang WS, Hur MS, Hu KS, et al. Surface anatomy of the lip elevator muscles for the treatment of gummy smile using botulinum toxin. Angle Orthod. 2009;79(1):70–7. https://doi.org/10.2319/091407-437.1.

    Article  PubMed  Google Scholar 

  88. Fabi SG, Massaki AN, Guiha I, Goldman MP. Randomized Split-face study to assess the efficacy and safety of abobotulinumtoxinA versus onabotulinumtoxinA in the treatment of melomental folds (depressor Anguli Oris). Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2015;41(11):1323–5. https://doi.org/10.1097/DSS.0000000000000501.

    Article  CAS  Google Scholar 

  89. Carruthers A, Carruthers J. Clinical indications and injection technique for the cosmetic use of botulinum A exotoxin. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 1998;24(11):1189–94. https://doi.org/10.1111/j.1524-4725.1998.tb04097.x.

    Article  CAS  Google Scholar 

  90. Andrade NN, Deshpande GS. Use of botulinum toxin (botox) in the management of masseter muscle hypertrophy: a simplified technique. Plast Reconstr Surg. 2011;128(1):24e–6e. https://doi.org/10.1097/PRS.0b013e3182174463.

    Article  CAS  PubMed  Google Scholar 

  91. Long H, Liao Z, Wang Y, Liao L, Lai W. Efficacy of botulinum toxins on bruxism: an evidence-based review. Int Dent J. 2012;62(1):1–5. https://doi.org/10.1111/j.1875-595X.2011.00085.x.

    Article  PubMed  Google Scholar 

  92. Pihut M, Ferendiuk E, Szewczyk M, Kasprzyk K, Wieckiewicz M. The efficiency of botulinum toxin type a for the treatment of masseter muscle pain in patients with temporomandibular joint dysfunction and tension-type headache. J Headache Pain. 2016;17:29. https://doi.org/10.1186/s10194-016-0621-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Choe SW, Cho WI, Lee CK, Seo SJ. Effects of botulinum toxin type A on contouring of the lower face. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2005;31(5):502–7; discussion 507–508. https://doi.org/10.1111/j.1524-4725.2005.31151.

    Article  CAS  Google Scholar 

  94. Kim JH, Shin JH, Kim ST, Kim CY. Effects of two different units of botulinum toxin type a evaluated by computed tomography and electromyographic measurements of human masseter muscle. Plast Reconstr Surg. 2007;119(2):711–7. https://doi.org/10.1097/01.prs.0000239453.67423.99.

    Article  CAS  PubMed  Google Scholar 

  95. Zhou R, Fei Y, Sun L, Guo J, Zhou X, Zhang X. BTX-A rejuvenation: regional botulinum toxin-a injection of the platysma in patients with facial sagging. Aesthet Plast Surg. 2019;43(4):1044–53. https://doi.org/10.1007/s00266-019-01396-4.

    Article  Google Scholar 

  96. Levy PM. Neurotoxins: current concepts in cosmetic use on the face and neck—jawline contouring/platysma bands/necklace lines. Plast Reconstr Surg. 2015;136(5 Suppl):80S–3S. https://doi.org/10.1097/PRS.0000000000001841.

    Article  CAS  PubMed  Google Scholar 

  97. Lee KC, Pascal AB, Halepas S, Koch A. What are the most commonly reported complications with cosmetic botulinum toxin type a treatments? J Oral Maxillofac Surg. 2020;78(7):1190.e1–9. https://doi.org/10.1016/j.joms.2020.02.016.

    Article  PubMed  Google Scholar 

  98. Ascher B, Rzany BJ, Grover R. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow’s feet: double-blind, placebo-controlled, dose-ranging study. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2009;35(10):1478–86. https://doi.org/10.1111/j.1524-4725.2009.01261.x.

    Article  CAS  Google Scholar 

  99. Sethi N, Singh S, DeBoulle K, Rahman E. A review of complications due to the use of botulinum toxin A for cosmetic indications. Aesthet Plast Surg. 2021;45(3):1210–20. https://doi.org/10.1007/s00266-020-01983-w.

    Article  Google Scholar 

  100. Coté TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 2005;53(3):407–15. https://doi.org/10.1016/j.jaad.2005.06.011.

    Article  PubMed  Google Scholar 

  101. Naumann M, Carruthers A, Carruthers J, et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Mov Disord Off J Mov Disord Soc. 2010;25(13):2211–8. https://doi.org/10.1002/mds.23254.

    Article  Google Scholar 

  102. Albrecht P, Jansen A, Lee JI, et al. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology. 2019;92(1):e48–54. https://doi.org/10.1212/WNL.0000000000006688.

    Article  CAS  PubMed  Google Scholar 

  103. Torres S, Hamilton M, Sanches E, Starovatova P, Gubanova E, Reshetnikova T. Neutralizing antibodies to botulinum neurotoxin type A in aesthetic medicine: five case reports. Clin Cosmet Investig Dermatol. 2014;7:11–7. https://doi.org/10.2147/CCID.S51938.

    Article  CAS  PubMed  Google Scholar 

  104. Ferreira MC, Salles AG, Gimenez R, Soares MFD. Complications with the use of botulinum toxin type a in facial rejuvenation: report of 8 cases. Aesthet Plast Surg. 2004;28(6):441–4. https://doi.org/10.1007/s00266-004-0031-7.

    Article  Google Scholar 

  105. Hanke CW, Narins RS, Brandt F, et al. A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2013;39(6):891–9. https://doi.org/10.1111/dsu.12160.

    Article  CAS  Google Scholar 

  106. Omoigui S, Irene S. Treatment of ptosis as a complication of botulinum toxin injection. Pain Med Malden Mass. 2005;6(2):149–51. https://doi.org/10.1111/j.1526-4637.2005.05029.x.

    Article  Google Scholar 

  107. Yazici B, Beden U. Use of 0.5% apraclonidine solution in evaluation of blepharoptosis. Ophthal Plast Reconstr Surg. 2008;24(4):299–301. https://doi.org/10.1097/IOP.0b013e31817f526a.

    Article  PubMed  Google Scholar 

  108. Kim YJ, Lim OK, Choi WJ. Are there differences between intradermal and intramuscular injections of botulinum toxin on the forehead? Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2020;46(12):e126–31. https://doi.org/10.1097/DSS.0000000000002379.

    Article  CAS  Google Scholar 

  109. Matarasso SL, Matarasso A. Treatment guidelines for botulinum toxin type a for the periocular region and a report on partial upper lip ptosis following injections to the lateral canthal rhytids. Plast Reconstr Surg 2001;108(1):208–214; discussion 215–217. doi:https://doi.org/10.1097/00006534-200107000-00033.

  110. Carruthers J, Carruthers A. Botulinum toxin A in the mid and lower face and neck. Dermatol Clin. 2004;22(2):151–8. https://doi.org/10.1016/s0733-8635(03)00118-9.

    Article  CAS  PubMed  Google Scholar 

  111. Brandt FS, Bellman B. Cosmetic use of botulinum a exotoxin for the aging neck. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 1998;24(11):1232–4. https://doi.org/10.1111/j.1524-4725.1998.tb04103.x.

    Article  CAS  Google Scholar 

  112. Obagi S, Golubets K. Mild to moderate dysphagia following very low-dose Abobotulinumtoxin A for Platysmal bands. J Drugs Dermatol JDD. 2017;16(9):929–30.

    PubMed  Google Scholar 

  113. Graber EM, Dover JS, Arndt KA. Two cases of herpes zoster appearing after botulinum toxin type A injections. J Clin Aesthetic Dermatol. 2011;4(10):49–51.

    Google Scholar 

  114. Cavallini M, Cirillo P, Fundarò SP, et al. Safety of botulinum toxin A in aesthetic treatments: a systematic review of clinical studies. Dermatol Surg Off Publ Am Soc Dermatol Surg Al. 2014;40(5):525–36. https://doi.org/10.1111/dsu.12463.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. Maja Magazin and Marissa K. Shoji have contributed equally to this work.

Authors and Affiliations

  1. Department of Ophthalmology, Medical College of Georgia at Augusta University, Augusta, GA, USA

    Maja Magazin

  2. Department of Ophthalmology, University of Miami, Bascom Palmer Eye Institute, Miami, FL, USA

    Marissa K. Shoji

  3. Department of Ophthalmology, University of Illinois of Chicago, Illinois Eye and Ear Infirmary, Chicago, IL, USA

    Ann Q. Tran

  4. Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA

    Andrea A. Tooley

Authors
  1. Maja Magazin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marissa K. Shoji
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ann Q. Tran
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Andrea A. Tooley
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea A. Tooley .

Editor information

Editors and Affiliations

  1. Stein Eye Institute, University of California, Los Angeles, Los Angeles, CA, USA

    Edmund Tsui

  2. Stein Eye Institute, University of California, Los Angeles, Los Angeles, CA, USA

    Simon S. M. Fung

  3. Department of Ophthalmology, Massachusetts Eye and Ear Harvard Medical School, Boston, MA, USA

    Rohan Bir Singh

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Magazin, M., Shoji, M.K., Tran, A.Q., Tooley, A.A. (2023). Injectables: Aesthetics and Cosmetics. In: Tsui, E., Fung, S.S.M., Singh, R.B. (eds) Current Advances in Ocular Surgery. Current Practices in Ophthalmology. Springer, Singapore. https://doi.org/10.1007/978-981-99-1661-0_1

Download citation

  • DOI: https://doi.org/10.1007/978-981-99-1661-0_1

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-99-1660-3

  • Online ISBN: 978-981-99-1661-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation